Monoclonal Antibodies
Loncastuximab Tesirine for Non-Hodgkin's Lymphoma
Fred Hutch/University of Washington Cancer Consortium, Seattle, WA
Targeting 11 different conditionsLoncastuximab TesirinePhase 2RecruitingLed by Stephen D. SmithResearch Sponsored by University of WashingtonEligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Disease-specific criteria:
- Group 4: Relapsed/refractory, CD19-negative B-NHL by both immunohistochemistry and flow cytometry (minimal to absent expression). Patients (Pts) must have had at least 1 prior therapy, and no alternative with a more favorable benefit/risk ratio in the judgment of the treating investigator
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Upup to 5 years
Awards & highlights
No Placebo-Only Group
Study Summary
This trial tests whether a targeted therapy drug shrinks tumors in patients with B-cell malignancies that have come back or does not respond to treatment.
Eligible Conditions
- Non-Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Lymphoproliferative Disorder
- B-Cell Lymphoma
- Non-Hodgkin's Lymphoma
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowSelect...
You have a specific disease that needs to meet certain criteria for inclusion in the study.
Select...
You have a type of non-Hodgkin lymphoma called B-NHL that has come back or is not responding to treatment. Tests have shown that you have very low or no expression of the CD19 protein. You have already tried at least one treatment before, and your doctor doesn't think there is a better treatment option for you.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall response rate (ORR)
Secondary outcome measures
Clinical benefit rate
Duration or response
Incidence of grade 3-5 drug-related toxicity
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (loncastuximab tesirine)Experimental Treatment1 Intervention
Patients receive loncastuximab tesirine IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Find a site
Who is running the clinical trial?
University of WashingtonLead Sponsor
1,684 Previous Clinical Trials
1,687,058 Total Patients Enrolled
Stephen D. SmithPrincipal Investigator
Fred Hutch/University of Washington Cancer Consortium2 Previous Clinical Trials
53 Total Patients Enrolled
Media Library
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has Loncastuximab Tesirine obtained regulatory clearance from the FDA?
"There is some evidence of Loncastuximab Tesirine's safety, so it earned a score of 2. The lack of efficacy data precludes the medication from receiving higher mark."
Answered by AI
Is this research currently open to participants?
"This investigation is not currently recruiting study participants, as it was last updated on November 2nd 2022. However, there are 3609 other medical trials actively searching for patients to enroll in their studies."
Answered by AI
Recent research and studies